APP and Alzheimer disease: Overall, our study demonstrates that low-frequency rTMS can ameliorate the deficits of cognitive and synaptic functions through reducing BACE1 and APP processing in APP23/PS45 double transgenic mice of AD, suggesting that low-frequency rTMS may serve as a highly effective anti-amyloid treatment in AD.